I
n the United States, prescription opioid use quadrupled to more than 240 million prescriptions annually from 1999 to 2010. 1 At the same time, rates of opioid misuse, abuse, addiction, and fatal and nonfatal overdoses increased for younger and older adults. [2] [3] [4] [5] In response to this epidemic, the Centers for Disease Control and Prevention (CDC) released guidelines for managing chronic pain that caution against opioid use and warn that the benefits for improving pain and function must outweigh the risks when prescribing opioids. 6 The short-term effectiveness of opioids for pain management has been documented. 7, 8 No study has demonstrated that long-term opioid use (≥3 months) is effective, while many studies have documented risks (e.g., falls, fractures, overdoses). 9 Despite this, long-term opioid use has increased in communitydwelling older adults. 10, 11 To our knowledge, no studies have described long-term opioid use in older adults living in nursing homes (NHs).
Managing pain in NHs is challenging, with many residents having their pain undertreated [12] [13] [14] [15] Prescribers must balance the risks associated with untreated or undertreated pain (e.g., dependence in activities of daily living anxiety, depression) [16] [17] [18] with potential risks of opioids. Opioids are prescribed to 60% of NH residents in persistent pain. 14, 19 Older NH residents may be uniquely vulnerable to the sedating side effects of opioids (even at therapeutic doses) and adverse drug events because of their older age, greater frailty, and higher burden of comorbidities and polypharmacy than in community-dwelling older adults, [20] [21] [22] [23] yet little is known about how opioids and concurrent pharmacological and nonpharmacological therapies for pain are being used in NHs despite the potential harms associated with long-term opioid use. 6, 9 Opioid prescribing guidelines and national campaigns have largely focused on younger adults and communitydwelling older adults and may not be applicable to NH residents despite the burden of pain and extensive analgesic use in this population. 6, [24] [25] [26] We conducted this study to estimate the prevalence of overall and long-term opioid use, describe patterns of opioid and other pharmacological and nonpharmacological pain management by length of opioid use, and describe variation in long-term opioid use by key resident characteristics.
METHODS

Study Design and Data Sources
This cross-sectional study (approved by the University of Massachusetts Medical School Internal Review Board) used routinely collected, federally required administrative data from 2012 for all NH residents in Medicare-and Medicaid-certified NHs (Minimum Data Set (MDS) 3.0; covering~96% of U.S. NHs) merged with facility characteristics data (Certification and Survey Provider Enhanced Reporting) and pharmacy claims (Medicare Part D). The MDS 3.0 is a standardized assessment conducted by trained, registered nurses and consists of more than 400 items to assess residents' health including medical conditions, cognitive and physical functioning, and pain and pain management. [27] [28] [29] Based on medical record review and interviews with staff and direct caregivers, assessments are conducted at admission and quarterly thereafter. Measures have demonstrated validity and reliability (kappa≥0.78 for pain management measures). 27 
Study Sample
Our cohort included Medicare beneficiaries who were long-stay residents (>100 consecutive days in NH) and had a MDS assessment between April 1, 2012, and June 30, 2012 (n = 602,122). The first eligible MDS assessment was selected. Long-stay residents were included because they generally require extensive, long-term assistance from NHs to manage their chronic disabilities. 30 After restricting to those aged 65 and older without a cancer diagnosis or receiving hospice care, 315,949 residents met inclusion and exclusion criteria applied for practical purposes (e.g., missing data; Supplementary Figure S1 ).
Opioid Use
We were conceptually interested in opioid use during 120 days of follow-up, which we operationalized using Medicare Part D claims. Part D claims provided information on the generic drug name (used to identify opioids), prescription fill date, days' supply, dosage form, and dosage strength. Opioids were classified according to their duration of action (short vs long acting). The number of prescribed opioids during the 120 days of follow-up was calculated. Dosage form was categorized as oral, injected, transdermal, or other.
We estimated cumulative days of opioid use during the 120-day study period based on opioid prescription fill dates plus days' supply, assuming that the opioid was used on the fill date and daily for as long as the medication was prescribed. 31 We assumed that residents with overlapping opioid prescriptions (e.g., filling a second opioid prescription with ≥1 days of opioid use still remaining from the previous prescription) used both medications simultaneously as prescribed. We categorized opioid use as longterm (≥90 days cumulative use during the 120 days) 32, 33 , medium-term (31-89 cumulative days), and short-term (1-30 days). We categorized the average daily dose in oral morphine equivalents (OMEs) using recent CDC guidelines as less than 50 mg, 50 to 89 mg, and 90 mg or more OMEs per day. 6, 34 Part D claims provide no information on the administration of pain medications. Although not specific to opioids, MDS assessments during follow-up (items J0100A and J0100B) were used to broadly describe pain management regimens in the preceding 5 days as scheduled or as needed (PRN).
Pain Management and Other Medications
Part D claims provided information on total number of nonopioid medications, alternative analgesics, pain adjuvants prescribed during the 120-day follow-up. Non-opioid pharmacotherapies included prescribed nonsteroidal antiinflammatory drugs (NSAIDS; excluding aspirin). The American Geriatrics Society 2009 guidelines 26 were used to identify pain adjuvants and other medications used for pain.
MDS assessments during follow-up provided information on potentially contraindicated psychopharmacological medication use in the 7 days preceding the MDS (anxiolytics, hypnotics). 6 We used the MDS because Part D did not cover benzodiazepines in 2012. We also measured the percentage of residents receiving two or more antipsychotics, anxiolytics, or hypnotics because concurrent use of two or more central nervous system-active medications with opioids can increase the risk of falls and fractures beyond that of opioid use alone. 9, 35 Guidelines recommend that persons receiving opioids receive nonpharmacological interventions. 6 MDS 3.0 item J0100C documented receipt of nonpharmacological pain management in the 5 days before the assessment. 27 
Resident Characteristics
Information on age (65-74, 76-84, ≥85), gender, race and ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, Asian, other), physical impairment, and cognitive impairment, which have been documented to influence opioid use, [12] [13] [14] [15] [16] 36 came from the MDS. Physical impairment was measured using the MDS activity of daily living (ADL) scale. 37 Cognitive impairment was classified using CMS definitions. 38 We also evaluated persistent (pain lasting ≥3 months), 26 and intermittent pain. 15 We considered resident characteristics that might be potential confounders, including length of NH stay (<1, 1-2, 2-3, ≥3 years), marital status (married vs other), comorbidities known to cause pain (e.g., arthritis, fractures), and total comorbidity burden (based on MDS 3.0 Section I; categorized into quartiles).
Analysis
Descriptive statistics were used to summarize resident characteristics by age group, medication use and characteristics of use by length of opioid use during follow-up, and length of opioid use by resident characteristics. Modified Poisson models with robust variance estimation (using generalized estimating equations and exchangeable correlation structure) were used to estimate crude and adjusted prevalence ratios (aPRs) with 95% confidence intervals (CIs) for resident characteristics and long-term opioid use. 39 Adjusted analyses included state of NH residence and all resident characteristics. We conducted analyses restricted to residents in persistent pain to provide further information on this vulnerable subgroup and to compare our results with those of prior studies. 12, 14, 15 Supplemental analyses examined potential selection bias due to loss to follow-up by estimating the prevalence of any opioid use in those who were censored (excluding those who died or received hospice care).
RESULTS
The mean age of long-stay residents was 84.4 AE 8.7; 76.2% were women, and 80.6% were non-Hispanic white. Median length of stay of was 2.1 years (interquartile range (IQR) 1.3-3.6; Table 1 ). Most residents were moderately or severely physically or cognitively impaired or both, with a higher prevalence of severe cognitive impairment and dementia in older age groups. More than 40% of residents had seven or more comorbidities, and painful comorbidities, including arthritis (32.8%; more prevalent in older groups), anxiety (25.8%), depression (54.5%), and diabetes mellitus (31.6%; more prevalent in younger groups) were common. Persistent pain occurred in 15.5% of residents and intermittent pain in 16.1%.
Thirty-two percent were prescribed any opioids during the 120 day follow-up period, with 10.4%, 6.5%, and 15.5% of all participants prescribed opioids for short-, medium-, and long-term, respectively ( Table 2 ). The most common opioids were hydrocodone (52.6%; see Supplementary Table S1 for further detail), tramadol (31.8%), fentanyl (12.5%), and oxycodone (11.8%). The majority of short-(99.0%), medium-(94.5%), and long-(65.7%) term opioid users were prescribed short-acting opioids only. Long-term opioid users were prescribed more longacting opioids (34.1% of long-term vs 1.0% of short-term users) and had higher average daily doses (16.0% of longterm users had average daily dose ≥90 mg OME/day vs 3.3% of short-term users). The majority of opioid prescriptions were oral formulations, although nearly onequarter of long-term users received transdermal prescriptions (fentanyl). The majority of long-term users received scheduled analgesics (97.0%), with 29.5% receiving PRN analgesics. Scheduled analgesic use was lower for shortterm (scheduled: 43.5%, PRN: 42.0%) and medium-term users (scheduled: 77.6%, PRN: 47.6%).
The median number of unique nonopioid medications prescribed during 120 days was 12 in opioid users (IQR 8-16) and 9 in nonusers (IQR 6-12). When examining other medications used during follow-up (Table 2) , 16 .1% of residents prescribed opioids had stand-alone prescription NSAID claims, versus 8.4% of nonusers. Pain adjuvants (32.9% of opioid users) and other medications used for pain (25.5% of opioid users) were more than twice as common in opioid users as in nonusers. Anxiolytics and hypnotics were more common in opioid users than nonusers (31.6% vs 17.5%), as were two or more psychopharmacologics (13.1% vs 8.0%) (see Supplementary Table S2 for specific medications). 35 .6% vs 9.6%) had greater overall opioid and long-term opioid use ( Figure 1) . Table 3 shows that resident factors associated with greater prevalence of long-term opioid use included being severely physically impaired (vs no or mild impairment; aPR = 1.25, 95% CI = 1.22-1.28) or women (vs men; aPR = 1.21, 95% CI = 1.18-1.23). Prevalence of long-term use was lower in racial and ethnic minorities than in nonHispanic whites: non-Hispanic blacks (aPR = 0.93 95% CI = 0.90-0.95), Hispanics (aPR = 0.84, 95% CI = 0.80-0.88), Asians (aPR = 0.69, 95% CI = 0.61-0.77), and other (aPR = 0.89, 95% CI = 0.80-0.99). Prevalence of longterm opioid use was lower in those with moderate to severe cognitive impairment (severe vs no or mild; aPR = 0.82, 95% CI = 0.79-0.83). When restricting to residents in persistent pain, aPRs were qualitatively similar albeit attenuated for gender and physical impairment (Supplementary Table S3 ).
In supplemental analyses of opioid use in residents excluded because of censoring (other than death or hospice), overall opioid use was higher than in our analytical sample (41.8% vs 32.4%; Supplementary Text S1).
DISCUSSION
We found that nearly one-third of long-stay residents in 2012 were prescribed opioids during 120 days of followup, with one in seven residents prescribed opioids long-term. We identified interesting patterns of nonopioid analgesic, adjuvant, and nonpharmacological pain management use in opioid users and nonusers that begin to fill knowledge gaps in NH resident pain management. Although we reported a lower prevalence of persistent pain than previous studies, 12,40 the extent to which this is due to the opioids, other medications, or methodologic differences cannot be disentangled. 15 Given that no studies have demonstrated the long-term effectiveness of opioids and concerns that NH residents may be more vulnerable to adverse side effects of opioids, 9,20-23 our findings inform discussions about improving opioid use with other pain management strategies in NHs.
The high prevalence of long-term opioid use in NHs is more than twofold the prescribing seen in communitydwelling older adults. 10, 11 This may be warranted due to residents' pain and painful comorbidity burden and the historical undertreatment of pain in this care setting, 12- 16,36 which has distressing consequences including poor quality of life, decreased physical functioning, anxiety, and depression. [16] [17] [18] Similar to community-dwelling populations, most residents received only short-acting opioids. 41 This may be insufficient for managing chronic pain, which may require scheduled, long-acting opioids for adequate pain management. 26 However, the risks of opioid use are not adequately understood in NHs, as few studies of opioid effectiveness and safety have included NH residents. 9, 42 The high frequency of fentanyl initiation in opioid-na€ ıve residents also raises concerns about suboptimal opioid prescribing. 43, 44 In community-dwelling populations, opioids have been linked to falls, fractures, overdoses, and all-cause mortality; further work is needed to characterize risks in NH residents. 6, 9 Our findings suggest that greater use of nonopioid analgesics and nonpharmacological pain management may be potential areas for improvement in NHs, although these recommendations are not without limitations. 6, 26 Nonopioid medications used for pain are recommended as firstline treatment for chronic nonmalignant pain and can be used concurrently with opioids to provide potentially greater benefits to residents. 6 We found that pain adjuvants and other medications for pain were prescribed only to approximately half of opioid users during follow-up. Whether this is appropriate remains unclear because these agents also have potential risks. For example, NSAIDS are known to be associated with hepatic, gastrointestinal, renal, and cardiovascular events in older adults and may not be appropriate opioid substitutes. 26, 35 American
Geriatrics Society and CDC guidelines recommend nonpharmacological pain management, which can be combined with opioid therapy to provide potentially greater pain relief to residents. 6, 45 We found that nonpharmacological therapies were used in only one-quarter of opioid users. Although we could not ascertain specific nonpharmacological interventions used with the MDS 3.0, common approaches in NHs include biofeedback, applying heat and cold, massage, physical therapy, nerve block, stretching and strengthening exercises, and electrical stimulation. 46 Their use-along with other nonopioid analgesics -are associated with short-term benefits and lower risks than opioids 6 but may have limited applicability to cognitively impaired residents and may be difficult to implement given NH staffing and reimbursement constraints.
We noted several potentially modifiable risk factors for opioid prescribing, particularly in long-term users. Long-term users had higher daily doses than short-and Percentages may not add up to 100% because of rounding.
a Short-acting opioids included codeine, dihydrocodeine, hydrocodone, hydromorphone, meperidine, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, tapentadol, and tramadol. Long-acting opioids included buprenorphine, butorphanol, transdermal fentanyl, hydromorphone extended release (ER), methadone, morphine ER, oxycodone ER, oxymorphone ER, tapentadol ER, and tramadol ER. Calculated by estimating average daily dose of each unique opioid prescription, converting each prescription to oral morphine equivalents, summing the oral morphine equivalents for all prescriptions, and dividing by estimated cumulative days of opioid use.
c Percentages add up to >100% because some participants were prescribed multiple opioids with different dosage forms.
d Antidepressents commonly used as adjuvants included desipramine, nortriptyline, amitriptyline, duloxetine, venlafaxine, and milnacipran. 26 Anticonvulsants included carbamazepine, gabapentin, lamotrigine, and pregabalin. Corticosteroids included dexamethasone, prednisone, prednisolone, and methylprednisolone. Muscle relaxants included baclofen, carisoprodol, chlorzoxazone, cyclobenzaprine, dantrolene, metaxalone, methocarbamol, orphenadrine, and tizanidine. Subcategory percentages may not add up to overall categorical percentages because some residents were prescribed multiple medications.
e Defined using MDS assessments during 120-day follow-up (excludes index MDS assessment).
medium-term users. Although long-term users may need higher doses because of greater opioid tolerance, many adverse events linked to opioids are dose-dependent, 9 and the CDC prescribing guidelines recommend reassessing individual risks and benefits at doses of 50 OME or more per day and avoiding or carefully justifying doses of 90 OME or more per day. 6 Opioid users had a high prevalence of anxiolytic and hypnotic use. Direct measurement of benzodiazepines was not possible because Part D did not cover them. Yet, before Part D, benzodiazepine use was more common than other anxiolytics and hypnotics in NHs. 47 Benzodiazepines should never be co-prescribed with opioids, 6 although further work is needed to evaluate this in NHs. Finally, 13% of opioid users received two or more medications known to increase the risks of falls and fractures during follow-up (antipsychotics, anxiolytics, hypnotics). 35 When possible, prescribers should optimize concurrent psychopharmacological use to address concerns about drug-drug interactions and the co-occurrence of anxiety and depression with pain, which can interfere with pain management. 6, 35 Although the use of antipsychotics has fallen since 2012, antipsychotics, anxiolytics, and hypnotics are still commonly used. 48, 49 Findings that long-term opioid use was higher in women, non-Hispanic whites, individuals with severe physical impairment, and those with no or mild cognitive impairment are consistent with prior studies examining the correlates of untreated or undertreated persistent pain in long-stay residents. 14, 15 Contrasting with prior studies, 14, 15 we did not observe a strong relationship between age and opioid use, perhaps because of the higher burden of certain painful comorbidities (e.g., arthritis) in those aged 85 and older, although caution is warranted when using long-term opioids in this population because of residents' frailty. Identifying whether some residents are more susceptible to opioid-related adverse events is warranted. This study has several strengths and limitations. National MDS 3.0 data linked to Part D claims provided national, comprehensive information on long-stay residents who were Medicare beneficiaries. We provided detailed information on opioid use not previously examined, including specific opioids used, dosage strength, and length of opioid use over 120 days of follow-up. We characterized nonopioid pharmacological alternatives for pain, nonpharmacological pain management, and concurrent psychopharmacological medication use. Although the data were from 2012, they provided an important, more-recent snapshot of opioid prescribing during the height of national opioid prescribing. 4, 14, 15 Although we had loss to follow-up by requiring residents to be in the NH for 120 days, the sensitivity analysis suggests that our estimates may be conservative because those lost to follow-up had higher opioid use. We recognize that classifying opioid use according to cumulative number of days discarded important information on patterns of opioid use. We believe this affected our results focusing on long-term opioid use minimally. Operationalizing medication use through Part D claims may overestimate opioid use if residents did not use medications; multiple opioid claims among those prescribed opioids suggest that this issue may be minimal. We cannot know from Part D claims how medications were administered, though data from MDS assessments show that most long-term opioid users received scheduled analgesics. We have limited information on indications for medication use, resulting in potential misclassification (e.g., medications classified as pain adjuvants when they are prescribed for other indications). We could not evaluate over-the-counter medications from Part D (e.g., over-the-counter NSAIDS). No information on resident or staff pain management preferences was available.
In conclusion, long-term opioid use in older NH residents is twice as prevalent as in community settings.
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Cautious and consistent monitoring of opioid doses; optimizing concurrent psychopharmacological medication use; and increasing use of nonopioid analgesics, adjuvants, and nonpharmacological interventions when appropriate may be warranted to improve the quality of opioid use in NHs.
Interventions to improve opioid prescribing should incorporate complex systems approaches that engage all providers, including physicians, nurses, pharmacists, and other staff, to improve opioid prescribing (e.g., through education, greater use of alternatives, adverse event monitoring). 50 Comparative effectiveness studies that focus on physical function, pain control and quality-of-life endpoints, and comparative safety studies of opioids in NHs could help healthcare providers, residents, and their families make informed decisions on opioid use. Sponsor's Role: None of the funders had a role in design, methods, data collection, analysis, or preparation of this manuscript.
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